Robert Baltera Jr. bought $59k of PALI
director at PALISADE BIO, INC.. 30,000 shares at an average of $1.98, traded Jul 1, 2026, filed Jul 6, 2026.
Score components
- +15RoleDirector
- +7Trade size$59k at market
- +3Relative to holdingsHoldings up 9%
- +4Price context30% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-032229, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | POpen-market purchase Common Stock | +20,000 | $1.98 | $40k | 356,904 | Jul 6, 2026 |
| Jul 2, 2026 | POpen-market purchase Common Stock | +10,000 | $1.98 | $20k | 366,904 | Jul 6, 2026 |
Related signals
Other insiders at PALISADE BIO, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | PALIbuy PALISADE BIO, INC. | Donald Allen Williams director | $29k 20,000 shares | +1% | |
| 36Weak | PALIbuy PALISADE BIO, INC. | Robert Baltera Jr. director | $89k 45,000 shares | +11% | |
| 37Weak | PALIbuy PALISADE BIO, INC. | Robert Baltera Jr. director | $102k 50,000 shares | +14% | |
| 42Moderate | PALISADE BIO, INC. | John David Finley CEO, CFO | $303k 146,798 shares | -40% | |
| 28Weak | PALISADE BIO, INC. | Mitchell Lawrence Jones Chief Medical Officer | $107k 51,880 shares | -36% | |
| 23Weak | PALISADE BIO, INC. | John David Finley CEO, CFO | $6,818 3,896 shares | -12% | |
| 13Weak | PALISADE BIO, INC. | Mitchell Lawrence Jones Chief Medical Officer | $3,481 1,989 shares | -13% | |
| 38Weak | PALIbuy PALISADE BIO, INC. | Donald Allen Williams director | $8,356 5,000 shares | +87% | |
| 29Weak | PALIbuy PALISADE BIO, INC. | Donald Allen Williams director | $9,400 5,000 shares | +687% | |
| 39Weak | PALISADE BIO, INC. | Donald Allen Williams director | $4,863 1,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.